THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.10] ID: TIP-MED-000194

Oral Magnesium Salts (Magnesium Oxide, Citrate & Bisglycinate — Nutritional)

Active Ingredient / Scientific Identity: Oral Magnesium Salts • Class: Essential Intracellular Divalent Cation (Cofactor for >300 ATP-Dependent Enzymatic Reactions, Neuromuscular Excitability, Cardiac Rhythm & Bone Matrix)

⚖️ Compare Profile
Generic / Entity NameOral Magnesium Salts (Magnesium Oxide, Citrate & Bisglycinate — Nutritional) ([10.10])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassEssential Intracellular Divalent Cation (Cofactor for >300 ATP-Dependent Enzymatic Reactio
Available Dosage FormsOral Tablets / Capsules: Magnesium Oxide 400 mg (~240 mg elemental Mg, low 4–10% bioavailability, high osmotic
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: STRICTLY RENAL-FUNCTION DEPENDENT! The kidneys are the sole route of regulatory magnesium excretion. Avoid all oral ma
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Oral Magnesium Salts (Magnesium Oxide, Citrate & Bisglycinate — Nutritional) (TIP-MED-000194, Reference Code [10.10]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Essential Intracellular Divalent Cation (Cofactor for >300 ATP-Dependent Enzymatic Reactions, Neuromuscular Excitability, Cardiac Rhythm & Bone Matrix). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.10], p. 131): Krampoff (Alkem—Mg Bisglycinate + Vit E/Carnitine), MgD3 (Mg Glycinate/Oxide + Vit D3), Magvion, Magnekon (Mg Oxide 400 mg), Magnex-G; Parenteral: Magnesium Sulphate (MgSO4 50% w/v — 500 mg/mL ampoules) — Strengths & Dosage Forms: Oral Tablets / Capsules: Magnesium Oxide 400 mg (~240 mg elemental Mg, low 4–10% bioavailability, high osmotic laxative effect), Magnesium Citrate / Magnesium Glycinate (Bisglycinate) 100–250 mg elemental Mg (high bioavailability, minimal diarrhoea); Parenteral Injection: MgSO4 50% (1 g/2 mL)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.10], p. 131): Krampoff (Alkem—Mg Bisglycinate + Vit E/Carnitine), MgD3 (Mg Glycinate/Oxide + Vit D3), Magvion, Magnekon (Mg Oxide 400 mg), Magnex-G; Parenteral: Magnesium Sulphate (MgSO4 50% w/v — 500 mg/mL ampoules) — Strengths & Dosage Forms: Oral Tablets / Capsules: Magnesium Oxide 400 mg (~240 mg elemental Mg, low 4–10% bioavailability, high osmotic laxative effect), Magnesium Citrate / Magnesium Glycinate (Bisglycinate) 100–250 mg elemental Mg (high bioavailability, minimal diarrhoea); Parenteral Injection: MgSO4 50% (1 g/2 mL)
Dosage Forms & Available Strengths:
Oral Tablets / Capsules: Magnesium Oxide 400 mg (~240 mg elemental Mg, low 4–10% bioavailability, high osmotic laxative effect), Magnesium Citrate / Magnesium Glycinate (Bisglycinate) 100–250 mg elemental Mg (high bioavailability, minimal diarrhoea); Parenteral Injection: MgSO4 50% (1 g/2 mL)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Essential Intracellular Divalent Cation (Cofactor for >300 ATP-Dependent Enzymatic Reactions, Neuromuscular Excitability, Cardiac Rhythm & Bone Matrix) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Essential Intracellular Divalent Cation (Cofactor for >300 ATP-Dependent Enzymatic Reactions, Neuromuscular Excitability, Cardiac Rhythm & Bone Matrix) for Prevention and treatment of hypomagnesaemia (induced by chronic Proton Pump Inhibitors [pantoprazole/omeprazole >1 year], loop/thiazide diuretics [furosemide/chlorthalidone], alcoholism, or diabetic osmotic diuresis); nocturnal leg cramps in the elderly; migraine prophylaxis; adjunct in osteoporosis and constipation (Mg Oxide/Hydroxide); Parenteral MgSO4: Eclampsia/pre-eclampsia, torsades de pointes ventricular tachycardia, and life-threatening acute severe asthma..

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and treatment of hypomagnesaemia (induced by chronic Proton Pump Inhibitors [pantoprazole/omeprazole >1 year], loop/thiazide diuretics [furosemide/chlorthalidone], alcoholism, or diabetic osmotic diuresis)
  • nocturnal leg cramps in the elderly
  • migraine prophylaxis
  • adjunct in osteoporosis and constipation (Mg Oxide/Hydroxide)
  • Parenteral MgSO4: Eclampsia/pre-eclampsia, torsades de pointes ventricular tachycardia, and life-threatening acute severe asthma

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Oral Supplementation / Leg Cramps / Deficiency: 200 mg to 400 mg Elemental Magnesium daily (in 1–2 divided doses). Follow physician prescription.

Administration & Meal Timing: Take WITH meals or at bedtime (taking with food improves absorption and reduces osmotic loose stools). | At bedtime (for nocturnal calf cramps and muscle relaxation/sleep) or divided with lunch and dinner.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT! The kidneys are the sole route of regulatory magnesium excretion. Avoid all oral magnesium supplements and magnesium-containing antacids/laxatives (Milk of Magnesia, Gelusil, Cremaffin) if eGFR <30 mL/min! Hepatic: Safe.
Elimination & Renal Adjustment:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT! The kidneys are the sole route of regulatory magnesium excretion. Avoid all oral magnesium supplements and magnesium-containing antacids/laxatives (Milk of Magnesia, Gelusil, Cremaffin) if eGFR <30 mL/min! Hepatic: Safe.
Hepatic Impairment Considerations:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT! The kidneys are the sole route of regulatory magnesium excretion. Avoid all oral magnesium supplements and magnesium-containing antacids/laxatives (Milk of Magnesia, Gelusil, Cremaffin) if eGFR <30 mL/min! Hepatic: Safe.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • STRICTLY CONTRAINDICATED in Severe Chronic Kidney Disease (eGFR <30 mL/min / ESRD), Myasthenia Gravis (magnesium blocks presynaptic acetylcholine release at the neuromuscular junction and precipitates acute respiratory paralysis!), and Heart Block (2nd/3rd degree AV block)!

Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT! The kidneys are the sole route of regulatory magnesium excretion. Avoid all oral magnesium supplements and magnesium-containing antacids/laxatives (Milk of Magnesia, Gelusil, Cremaffin) if eGFR <30 mL/min! Hepatic: Safe.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Osmotic loose stools / diarrhoea and abdominal cramping (most prominent with poorly absorbed Magnesium Oxide/Sulphate; minimal with chelated Magnesium Glycinate!).
  • Hypermagnesaemia in Renal Impairment (Serum Mg2+ >2.5–4.0 mg/dL: loss of deep tendon reflexes [patellar areflexia at >4–5 mg/dL], flushing, hypotension, lethargy, somnolence, respiratory muscle paralysis, complete heart block, and cardiac arrest!).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Chelation Blockade (Space by ≥2–4 Hours!): Magnesium chelates and blocks absorption of Fluoroquinolones (ciprofloxacin, levofloxacin), Tetracyclines (doxycycline), Oral Bisphosphonates (alendronate), Levothyroxine, Gabapentin, and Integrase Inhibitors! Potentiates neuromuscular blockers and nifedipine hypotension

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 1. Differentiate salts: If prescribed for muscle cramps or sleep without wanting loose motions, Magnesium Glycinate (Bisglycinate) is gentle on the bowel, whereas Magnesium Oxide draws water into the gut and acts as a laxative. 2. Keep a strict 2-to-4 hour gap from thyroid pills, antibiotics, and bone (bisphosphonate) tablets. 3. If an elderly patient has been taking Pantoprazole/Omeprazole AND Furosemide/Chlorthalidone for years and complains of severe night-time calf cramps, check Serum Magnesium and Potassium.
  • Meal & Clock Timing Instruction: Take WITH meals or at bedtime (taking with food improves absorption and reduces osmotic loose stools). (At bedtime (for nocturnal calf cramps and muscle relaxation/sleep) or divided with lunch and dinner.)
  • Missed Dose Protocol: Take with the next meal or bedtime; never double.
  • Geriatric Dispensing Pearl: Always check eGFR before dispensing any Magnesium supplement (or Mg-containing antacid/laxative) to an elderly CGHS patient—in Stage 4–5 CKD, magnesium rapidly accumulates and causes lethargy, falls, and heart block.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Tablets / Capsules: Magnesium Oxide 400 mg (~240 mg elemental Mg, low 4–10% bioavailability, high osmotic laxative effect), Magnesium Citrate / Magnesium Glycinate (Bisglycinate) 100–250 mg elemental Mg (high bioavailability, minimal diarrhoea); Parenteral Injection: MgSO4 50% (1 g/2 mL)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.10] (p. 131)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.